Robert W Ross

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect
    Robert W Ross
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:1247-53. 2008
  2. ncbi Hormone-refractory prostate cancer: choosing the appropriate treatment option
    Robert W Ross
    Harvard Medical School, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncology (Williston Park) 21:185-93; discussion 194, 199-200. 2007
  3. ncbi Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer
    Robert W Ross
    Dana Farber Cancer Institute, Dana 710 C, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:842-7. 2008
  4. ncbi Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:308-12. 2008
  5. ncbi Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy
    Toni K Choueiri
    Dana Farber Cancer Institute Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer 115:981-7. 2009
  6. ncbi Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone
    Oliver Sartor
    Dana Farber Cancer Institute, Boston, MA, USA
    Clin Genitourin Cancer 7:E90-2. 2009
  7. ncbi Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy
    Robert W Ross
    Center for Molecular Imaging Research, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Imaging 33:301-5. 2009
  8. ncbi A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
    Robert W Ross
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:521-6. 2008
  9. ncbi Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial
    Robert W Ross
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:4777-84. 2012
  10. ncbi Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 30:507-12. 2012

Detail Information

Publications17

  1. ncbi Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect
    Robert W Ross
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:1247-53. 2008
    ..The purpose of this study was to compare predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone-sensitive prostate cancer (HSPC) either with (M+) or without (M-) metastases...
  2. ncbi Hormone-refractory prostate cancer: choosing the appropriate treatment option
    Robert W Ross
    Harvard Medical School, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncology (Williston Park) 21:185-93; discussion 194, 199-200. 2007
    ..Several promising novel therapies are in late-stage testing and will hopefully provide more treatment options for these patients...
  3. ncbi Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer
    Robert W Ross
    Dana Farber Cancer Institute, Dana 710 C, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:842-7. 2008
    ..Androgen-deprivation therapy (ADT) is the most common and effective systemic therapy for advanced prostate cancer. We hypothesized that germline genetic variation in the androgen axis would improve the efficacy of ADT...
  4. ncbi Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:308-12. 2008
    ..To evaluate the efficacy of docetaxel/carboplatin (DC)-based chemotherapy as first- and second-line chemotherapy for patients with hormone-refractory prostate cancer (HRPC)...
  5. ncbi Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy
    Toni K Choueiri
    Dana Farber Cancer Institute Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer 115:981-7. 2009
    ....
  6. ncbi Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone
    Oliver Sartor
    Dana Farber Cancer Institute, Boston, MA, USA
    Clin Genitourin Cancer 7:E90-2. 2009
    ..We hypothesized that SRDA5 inhibition in combination with ketoconazole would mitigate progression after treatment with ketoconazole alone...
  7. ncbi Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy
    Robert W Ross
    Center for Molecular Imaging Research, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Imaging 33:301-5. 2009
    ..Six (23%) of the 26 patients, previously believed to be node negative, tested lymph node positive by LNMRI. A total of nine positive lymph nodes were identified in these six patients, none of which were enlarged based on size criteria...
  8. ncbi A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
    Robert W Ross
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:521-6. 2008
    ..The authors conducted a phase 2 trial of docetaxel plus carboplatin chemotherapy in this disease setting...
  9. ncbi Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial
    Robert W Ross
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:4777-84. 2012
    ..Treatment of high-risk localized prostate cancer remains inadequate. The authors performed a phase 2 multicenter trial of neoadjuvant docetaxel plus bevacizumab before radical prostatectomy...
  10. ncbi Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 30:507-12. 2012
    ..Vandetanib in combination with docetaxel was assessed in patients with advanced urothelial cancer (UC) who progressed on prior platinum-based chemotherapy...
  11. ncbi Utility of a new bolus-injectable nanoparticle for clinical cancer staging
    Mukesh Harisinghani
    Center for Molecular Imaging Research, Massachusetts General Hospital, Boston, MA 02129 2060, USA
    Neoplasia 9:1160-5. 2007
    ..In this study, we report on the use of a new, bolus-injectable, carboxymethyl dextran-based magnetic nanoparticle (MNP), ferumoxytol, to improve detection in loco-regional lymph nodes by magnetic resonance imaging (MRI)...
  12. ncbi Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study
    Robert W Ross
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:8109-13. 2005
    ..We assessed factors predicting a successful tumor harvest from bone marrow biopsies (BMBx) in castration-resistant metastatic prostate cancer patients...
  13. ncbi A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study
    Robert W Ross
    Division of Solid Tumor Oncology, Department of Medicine, Dana Farber Cancer Institute, Boston, MA, USA
    Lancet Oncol 13:1105-13. 2012
    ..Survival for patients with castration-resistant prostate cancer is highly variable. We assessed the effectiveness of a whole-blood RNA transcript-based model as a prognostic biomarker in castration-resistant prostate cancer...
  14. ncbi Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy
    Robert W Ross
    Dana Farber Cancer Institute, Harvard Medical School Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:5195-8. 2005
    ....
  15. ncbi A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation
    Mukesh G Harisinghani
    Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Urology 66:1066-71. 2005
    ..To evaluate whether lymphotrophic nanoparticle-enhanced magnetic resonance imaging (LNMRI) can be used as a method for detecting metastatic disease within retroperitoneal nodes in patients with testicular cancer...
  16. ncbi Osteoporosis in men treated with androgen deprivation therapy for prostate cancer
    Robert W Ross
    University of California-San Francisco Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California, USA
    J Urol 167:1952-6. 2002
    ..The osteoporotic fracture incidence and bone mineral density should be regularly incorporated into studies involving the hormonal treatment of prostate cancer...
  17. ncbi Predicting outcomes in prostate cancer: how many more nomograms do we need?
    Robert W Ross
    J Clin Oncol 25:3563-4. 2007